Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients

Inclusion Criteria: * Age ≥ 18 years old. * Patients with biopsy confirmed diagnosis breast cancer and with stage II and stage III breast cancer according to the American Joint Committee on Cancer (TNM staging system of breast cancer). * Patients with performance status \<2 according to Eastern Cooperative Oncology Group (ECOG) score. * Adequate baseline hematologic values (absolute neutrophilic count ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L and hemoglobin level ≥ 10 g/dl). * Patients with adequate liver function (serum bilirubin \< 1.2 mg/dl) and adequate renal function (serum creatinine \< 1.5 mg/d). Exclusion Criteria: * Patients with prior exposure to anthracyclines in the last 6 months. * Patients with evidence of metastasis at the initial assessment. * Concomitant use of antioxidant vitamins (vitamin A, C, E). * Presence of clinical evidence for severe cardiac illness (angina pectoris, uncontrolled hypertension, arrhythmias and left ventricular ejection fraction \<50%). * Patients with inflammatory diseases (ulcerative colitis, rheumatoid arthritis). * Patients with conditions associated with oxidative stress (smoking, tuberculosis, comorbid obesity). * Patients who are candidates for monoclonal antibodies such as Trastuzumab and other targeted therapy (HER2 positive patients). * Patients with active liver disease (cirrhosis, fatty liver, hepatitis C, etc..). * Patients with myopathy. * Patients with renal impairment, including those with end-stage renal disease a…